Next Article in Journal
Personalized Lifestyle Interventions for Prevention and Treatment of Obesity-Related Cancers: A Call to Action
Previous Article in Journal
Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666

by
Andrea Cavazzoni
1,*,†,
Graziana Digiacomo
1,†,
Roberta Alfieri
1,*,
Silvia La Monica
1,
Claudia Fumarola
1,
Maricla Galetti
2,
Mara Bonelli
1,
Daniele Cretella
1,
Valeria Barili
1,
Alessandra Zecca
3,
Elisa Giovannetti
4,5,
Michelangelo Fiorentino
6,
Marcello Tiseo
1,
Pier Giorgio Petronini
1,‡ and
Andrea Ardizzoni
6,‡
1
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
2
Italian Workers’ Compensation Authority (INAIL) Research Center, 43126 Parma, Italy
3
Department of Infectious Diseases and Hepatology, University Hospital of Parma, 43126 Parma, Italy
4
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, 1081HV Amsterdam, The Netherlands
5
Fondazione Pisana per la Scienza, San Giuliano Terme, 56017 Pisa, Italy
6
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy
*
Authors to whom correspondence should be addressed.
These authors share equal contribution.
These authors share equal senior authorship.
Cancers 2025, 17(8), 1254; https://doi.org/10.3390/cancers17081254
Submission received: 4 March 2025 / Accepted: 12 March 2025 / Published: 8 April 2025

Error in Figure

In the original publication [1], there was a mistake in Figure 2C,D as published. An incorrect image of Actin was inserted as a loading control. The corrected Figure 2 appears below. Additionally, the associated Supplementary Figure S7 has been updated. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 2. Effect of pemetrexed on PD-L1 expression in A549 cell line. (A) A549 cells were treated with 100 nM pemetrexed for the indicated period of time and PD-L1 mRNA level, evaluated by RT-PCR, was reported. (B) Time-dependent modulation (100 nM pemetrexed) and (C) dose-dependent modulation (72 h) of PD-L1 protein expression in A549 cells were evaluated by western blotting. A549 cells were continuously exposed to 500 nM pemetrexed for the indicated period of time or treated for 24 h and, after drug removal, the cells were incubated with fresh medium for 24 h or 48 h. At the indicated times, total PD-L1 protein, membrane PD-L1 protein, and PD-L1 mRNA were quantified by western blotting (D), flow cytometry (E), and RT-PCR (F), respectively. * p < 0.05; ** p < 0.01; *** p < 0.001. Data in (A), (E), and (F) are mean values ± SD of three independent experiments. Results in (BD) are representative of three independent experiments.
Figure 2. Effect of pemetrexed on PD-L1 expression in A549 cell line. (A) A549 cells were treated with 100 nM pemetrexed for the indicated period of time and PD-L1 mRNA level, evaluated by RT-PCR, was reported. (B) Time-dependent modulation (100 nM pemetrexed) and (C) dose-dependent modulation (72 h) of PD-L1 protein expression in A549 cells were evaluated by western blotting. A549 cells were continuously exposed to 500 nM pemetrexed for the indicated period of time or treated for 24 h and, after drug removal, the cells were incubated with fresh medium for 24 h or 48 h. At the indicated times, total PD-L1 protein, membrane PD-L1 protein, and PD-L1 mRNA were quantified by western blotting (D), flow cytometry (E), and RT-PCR (F), respectively. * p < 0.05; ** p < 0.01; *** p < 0.001. Data in (A), (E), and (F) are mean values ± SD of three independent experiments. Results in (BD) are representative of three independent experiments.
Cancers 17 01254 g002

Reference

  1. Cavazzoni, A.; Digiacomo, G.; Alfieri, R.; La Monica, S.; Fumarola, C.; Galetti, M.; Bonelli, M.; Cretella, D.; Barili, V.; Zecca, A.; et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cavazzoni, A.; Digiacomo, G.; Alfieri, R.; La Monica, S.; Fumarola, C.; Galetti, M.; Bonelli, M.; Cretella, D.; Barili, V.; Zecca, A.; et al. Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666. Cancers 2025, 17, 1254. https://doi.org/10.3390/cancers17081254

AMA Style

Cavazzoni A, Digiacomo G, Alfieri R, La Monica S, Fumarola C, Galetti M, Bonelli M, Cretella D, Barili V, Zecca A, et al. Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666. Cancers. 2025; 17(8):1254. https://doi.org/10.3390/cancers17081254

Chicago/Turabian Style

Cavazzoni, Andrea, Graziana Digiacomo, Roberta Alfieri, Silvia La Monica, Claudia Fumarola, Maricla Galetti, Mara Bonelli, Daniele Cretella, Valeria Barili, Alessandra Zecca, and et al. 2025. "Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666" Cancers 17, no. 8: 1254. https://doi.org/10.3390/cancers17081254

APA Style

Cavazzoni, A., Digiacomo, G., Alfieri, R., La Monica, S., Fumarola, C., Galetti, M., Bonelli, M., Cretella, D., Barili, V., Zecca, A., Giovannetti, E., Fiorentino, M., Tiseo, M., Petronini, P. G., & Ardizzoni, A. (2025). Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666. Cancers, 17(8), 1254. https://doi.org/10.3390/cancers17081254

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop